Harvard In Tech and PRLX to Present Live Webinar "COVID-19 Testing, Telehealth, Technology and Data Driven Solutions"
March 17 2020 - 6:21AM
InvestorsHub NewsWire
Harvard In Tech and Parallax Health Sciences to Present Live
Webinar “COVID-19 Testing, Telehealth, Technology and Data Driven
Solutions” Wednesday, March 18th at 1 PM EDT
NEW YORK, NY -- March 17, 2020 -- InvestorsHub NewsWire
-- Parallax Health Sciences,
Inc. (PRLX)
(''Parallax'' or the ''Company''), an outcome-driven connected
healthcare company, today announced that in collaboration with
Harvard In Tech, Harvard University's official Alumni Group for
Technology, there will be a jointly hosted live webinar, entitled
“c-19 Testing, Telehealth, Technology and Data Driven Solutions” to
be broadcast at 1:00 PM EDT on Wednesday, March 18th from
Parallax’s Good Health Outcomes website and will be available
at www.goodhealthoutcomes.com also
free to the public.
The event will be moderated by Harvard In Tech Executive
Director, Krysia Lenzo and will feature Dr. David Stark, President
of Parallax Diagnostics and Nathaniel Bradley, President of
Parallax Health Management. The interactive webinar will present
the current state and challenges facing the United States medical
community and its citizens affected by the coronavirus pandemic.
The discussion will last 20 minutes and includes a questions and
answers session that will focus on diagnostic testing, the
importance of remote patient monitoring (RPM), and the key
technologies and data related to public and private solutions
addressing the current crisis.
"With COVID-19 affecting our global community, Harvard In Tech
is partnering with Parallax Health Sciences to discuss ways
technology can mitigate the spread of the coronavirus,” commented
Krysia Lenzo, Executive Director of Harvard In Tech. Ms. Lenzo
further stated, “We are thankful for Parallax Health Sciences
sharing their knowledge with Harvard In Tech as we try to address
solutions for the current pandemic."
“We are thankful to see the attention coming into the healthcare
community from high-level interest groups and high-quality
institutions such as Harvard In Tech,” stated Dr. David Stark,
President of Parallax Diagnostics, Inc. Dr. Stark elaborated,
“We have 510(K) approved technology and secure patent strength that
allows for partnering with companies focusing on point-of-care
(POC) research to widen in scope and or accelerate their market
share.”
Nathaniel Bradley, Chief Technology Officer of the Company and
President of Parallax Health Management stated, “Data driven and
behavioral technologies are well positioned to counter and deal
with the current medical crisis within the U.S. and abroad.”
Mr. Bradley continued, “we are grateful that Harvard In Tech has
provided the opportunity to share how we believe we will prevail as
a global community over the coronavirus.”
As previously announced, the Company has an ongoing strategic
initiative for the creation of a rapid screening test on its
VT-1000 diagnostics device for COVID-19, coronavirus testing that
when soon available will produce results within 15 minutes.
The Company has already received 26-Federal Drug Administration,
(“FDA”) 510(K) approvals for biomarkers used in conjunction with
the VT-1000 desktop unit.
About Harvard In Tech
Harvard In Tech is Harvard University's official Alumni Group
for Technology. Our mission is to further the development of
technology through encouraging innovation, providing Harvard alumni
technologists with resources and networks, and promoting
technological activity throughout the Harvard community. We are
currently active in New York City, Seattle, San Francisco, and
Tokyo. To stay up to date about future events, please
visit: www.harvardintech.com
About Parallax Health Sciences
Parallax Health Sciences is a leading-edge technology,
outcome-driven telehealth company that allows for cost-effective
remote diagnosis, treatment, and monitoring of patients through
proprietary platforms of integrated products and services. The
Company's interoperable novel applications provide patients
point-of-care testing and monitoring with information communicated
via internet-based mobile phone applications that are agnostic as
to operating system and are built on highly sophisticated data
analytics. Information is retrieved in real-time by physicians who
are monitoring patients with chronic diseases or through biometric
feedback for health-related behavior modification, and is automated
for integration into electronic health records. The Company's
products and offerings capitalize on the digital transformation in
healthcare for improved patient compliance, diagnosis and
treatment, and support healthcare system cost savings and
efficiencies. For more information, please
visit www.parallaxhealthsciences.com or www.parallaxcare.com.
Investor
Contact:
Paul Arena,
CEO
paul@parallaxcare.com
cell
404-915-8449
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From May 2024 to Jun 2024
Parallax Health Sciences (CE) (USOTC:PRLX)
Historical Stock Chart
From Jun 2023 to Jun 2024